Disease · MONDO_0005099
Comparisons in its trials22
Comparisons Trial comparisons calculated in the trials shown here, most participants first. A comparison in one of these trials does not always compare a treatment for the disease, so read the two groups.
1 to 20 of 22
Download this page as JSON| Comparison | Group 1, with the outcome | Group 2, with the outcome | Participants | Trial | Source |
|---|---|---|---|---|---|
| Galantamine vs Placebo: Mortality | 1 of 30 | 4 of 30 | 60 | NCT02872857 | Trial comparisons |
| Galantamine vs Placebo: deaths from any cause | 1 of 30 | 4 of 30 | 60 | NCT02872857 | Trial comparisons |
| Galantamine vs Placebo: Tolerability as Assessed by the Number of Participants Who Stop Study Medication Due to Adverse Event Possibly Associated With Study Drug | 1 of 30 | 1 of 30 | 60 | NCT02872857 | Trial comparisons |
| Galantamine vs Placebo: serious adverse events | 17 of 30 | 17 of 30 | 60 | NCT02872857 | Trial comparisons |
| Tiopronin, Hunt Hess Grade I-V vs Sugar Pill, Hunt Hess Grade I-V: deaths from any cause | 4 of 29 | 3 of 27 | 56 | NCT01095731 | Trial comparisons |
| Tiopronin, Hunt Hess Grade I-V vs Sugar Pill, Hunt Hess Grade I-V: serious adverse events | 6 of 29 | 9 of 27 | 56 | NCT01095731 | Trial comparisons |
| Acetaminophen vs Bromocriptine and Acetaminophen: deaths from any cause | 0 of 21 | 1 of 26 | 47 | NCT03496545 | Trial comparisons |
| Acetaminophen vs Bromocriptine and Acetaminophen: serious adverse events | 0 of 21 | 1 of 26 | 47 | NCT03496545 | Trial comparisons |
| Simvastatin vs Control: serious adverse events | 0 of 21 | 0 of 21 | 42 | NCT00795288 | Trial comparisons |
| Dantrolene vs Placebo: Liver Toxicity | 1 of 16 | 0 of 15 | 31 | NCT01024972 | Trial comparisons |
| Dantrolene vs Placebo: Hyponatremia | 7 of 16 | 10 of 15 | 31 | NCT01024972 | Trial comparisons |
| Dantrolene vs Placebo: In-hospital Mortality | 2 of 16 | 1 of 15 | 31 | NCT01024972 | Trial comparisons |
| Dantrolene vs Placebo: serious adverse events | 4 of 16 | 2 of 15 | 31 | NCT01024972 | Trial comparisons |
| Tirofiban Hydrochloride (AGGRASTAT®) vs Standard of Care Control Arm: Number of Participants With Delayed Cerebral Ischemia /Clinical Vasospasm | 1 of 18 | 4 of 12 | 30 | NCT03691727 | Trial comparisons |
| Tirofiban Hydrochloride (AGGRASTAT®) vs Standard of Care Control Arm: Number of Participants With Intracranial Hemorrhage (Symptomatic and Asymptomatic) | 2 of 18 | 1 of 12 | 30 | NCT03691727 | Trial comparisons |
| Tirofiban Hydrochloride (AGGRASTAT®) vs Standard of Care Control Arm: deaths from any cause | 1 of 18 | 0 of 12 | 30 | NCT03691727 | Trial comparisons |
| Tirofiban Hydrochloride (AGGRASTAT®) vs Standard of Care Control Arm: serious adverse events | 18 of 18 | 12 of 12 | 30 | NCT03691727 | Trial comparisons |
| Simvastatin vs Control: Cerebral Autoregulation During Peak Period of Vasospasm Risk | 2 of 13 | 2 of 12 | 25 | NCT00795288 | Trial comparisons |
| GSK2256294 vs Placebo: Number of Participants With New Stroke on Hospital Discharge Imaging | 1 of 10 | 1 of 9 | 19 | NCT03318783 | Trial comparisons |
| GSK2256294 vs Placebo: deaths from any cause | 0 of 10 | 1 of 9 | 19 | NCT03318783 | Trial comparisons |
diseases-2026-09-18-0.1.0
Sources 6
- ClinicalTrials.gov's posted results, through CTTI's AACTFreely available. Acknowledgement requested
- ChEMBL, through Open TargetsCC BY-SA 3.0
- ClinicalTrials.govNo license stated
- NLM's MeSHNLM's terms
- Open TargetsCC0 1.0
- PubMedNLM's terms
Each source's terms
- ClinicalTrials.gov's posted results, through CTTI's AACTClinicalTrials.gov data via Aggregate Analysis of ClinicalTrials.gov (AACT), CTTI. CTTI makes its materials freely available and requests acknowledgement. https://aact.ctti-clinicaltrials.org/documentation/299
- ChEMBL, through Open TargetsCC BY-SA 3.0, for the parts from ChEMBL. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- ClinicalTrials.govnone stated
- NLM's MeSHNLM's
- Open TargetsCC0 1.0. Open Targets asks that users cite its latest paper: Buniello et al. 2025, Open Targets Platform: facilitating therapeutic hypotheses building in drug discovery, Nucleic Acids Research 53(D1):D1467, PMID 39657122. Read on 8 Nov 2026 at https://platform-docs.opentargets.org/licence
- PubMedNLM's terms
ClinicalTrials.gov's data carry an international copyright outside the United States: https://clinicaltrials.gov/about-site/terms-conditions.
For software
Read this list from software.
Twenty rows a page, as JSON. No key.
GET https://conductscience.org/api/diseases/v1/MONDO_0005099/comparisons